134 related articles for article (PubMed ID: 9073313)
21. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Hensley ML; Schuchter LM; Lindley C; Meropol NJ; Cohen GI; Broder G; Gradishar WJ; Green DM; Langdon RJ; Mitchell RB; Negrin R; Szatrowski TP; Thigpen JT; Von Hoff D; Wasserman TH; Winer EP; Pfister DG
J Clin Oncol; 1999 Oct; 17(10):3333-55. PubMed ID: 10506637
[TBL] [Abstract][Full Text] [Related]
22. Effect of amifostine on neuroblastoma during high dose chemotherapy: in vivo and in vitro investigations.
Renner S; Krümpelmann S; Bruchelt G; Wiesinger H; Niethammer D; Klingebiel T
Anticancer Res; 2000; 20(6B):4531-8. PubMed ID: 11205300
[TBL] [Abstract][Full Text] [Related]
23. Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients.
Korst AE; van der Sterre ML; Gall HE; Fichtinger-Schepman AM; Vermorken JB; van der Vijgh WJ
Clin Cancer Res; 1998 Feb; 4(2):331-6. PubMed ID: 9516919
[TBL] [Abstract][Full Text] [Related]
24. [Alteration of radiation-induced hematotoxicity by amifostine (ethyol)].
Momm F; Bechtold C; Fischer K; Tsekos A; Henke M
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():2-5. PubMed ID: 10584132
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats.
Herman EH; Zhang J; Chadwick DP; Ferrans VJ
Cancer Chemother Pharmacol; 2000; 45(4):329-34. PubMed ID: 10755322
[TBL] [Abstract][Full Text] [Related]
26. Enhancement of fotemustine (Muphoran) cytotoxicity by amifostine in malignant melanoma cell lines.
Merlin JL; Marchal S; Ramacci C; Berlion M; Poullain MG
Anticancer Drugs; 2002 Feb; 13(2):141-7. PubMed ID: 11901306
[TBL] [Abstract][Full Text] [Related]
27. Amifostine: is there evidence of tumor protection?
Koukourakis MI
Semin Oncol; 2003 Dec; 30(6 Suppl 18):18-30. PubMed ID: 14727237
[TBL] [Abstract][Full Text] [Related]
28. Amifostine for protection from antineoplastic drug toxicity.
Foster-Nora JA; Siden R
Am J Health Syst Pharm; 1997 Apr; 54(7):787-800. PubMed ID: 9099346
[TBL] [Abstract][Full Text] [Related]
29. Effect of amifostine (Ethyol) on the development of extraembryonic blood vessels in chick embryos.
Höper J; Hanjalic A; Sauer R; Plasswilm L
Strahlenther Onkol; 1999 Jan; 175(1):28-31. PubMed ID: 9951515
[TBL] [Abstract][Full Text] [Related]
30. Amifostine and hematologic effects.
Sriswasdi C; Jootar S; Giles FJ
J Med Assoc Thai; 2000 Apr; 83(4):374-82. PubMed ID: 10808697
[TBL] [Abstract][Full Text] [Related]
31. Amifostine, a reactive oxigen species scavenger with radiation- and chemo-protective properties, inhibits in vitro platelet activation induced by ADP, collagen or PAF.
Porta C; Maiolo A; Tua A; Grignani G
Haematologica; 2000 Aug; 85(8):820-5. PubMed ID: 10942928
[TBL] [Abstract][Full Text] [Related]
32. Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.
Korst AE; Boven E; van der Sterre ML; Fichtinger-Schepman AM; van der Vijgh WJ
Br J Cancer; 1997; 75(10):1439-46. PubMed ID: 9166935
[TBL] [Abstract][Full Text] [Related]
33. Amifostine as a protector against cisplatin-induced toxicity in nude mice.
Johnsson A; Wennerberg J
Acta Oncol; 1999; 38(2):247-53. PubMed ID: 10227448
[TBL] [Abstract][Full Text] [Related]
34. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol).
Capizzi RL
Eur J Cancer; 1996; 32A Suppl 4():S5-16. PubMed ID: 8976816
[TBL] [Abstract][Full Text] [Related]
35. Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study.
De Souza CA; Santini G; Marino G; Nati S; Congiu AM; Vigorito AC; Damasio E
Braz J Med Biol Res; 2000 Jul; 33(7):791-8. PubMed ID: 10881054
[TBL] [Abstract][Full Text] [Related]
36. Amifostine does not protect malignant lymphoma cell lines from the cytotoxic effects of various chemotherapeutics in vitro.
Kuittinen O; Ruokolainen H; Turpeenniemi-Hujanen T
Leuk Lymphoma; 2001 Jul; 42(3):507-10. PubMed ID: 11699416
[TBL] [Abstract][Full Text] [Related]
37. Immunocytochemical analysis of apoptotic bone marrow cells after treatment of mice with WR-2721 and chemotherapeutic drugs.
Mazur L; Czyzewska A
Folia Histochem Cytobiol; 2001; 39(2):63-6. PubMed ID: 11374841
[TBL] [Abstract][Full Text] [Related]
38. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained.
Taylor CW; Wang LM; List AF; Fernandes D; Paine-Murrieta GD; Johnson CS; Capizzi RL
Eur J Cancer; 1997 Sep; 33(10):1693-8. PubMed ID: 9389935
[TBL] [Abstract][Full Text] [Related]
39. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by Wr-2721.
Wasserman TH; Phillips TL; Ross G; Kane LJ
Cancer Clin Trials; 1981; 4(1):3-6. PubMed ID: 6260393
[TBL] [Abstract][Full Text] [Related]
40. Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancer.
Dunn TA; Schmoll HJ; Grünwald V; Bokemeyer C; Casper J
Anticancer Drugs; 1996 Sep; 7(7):795-9. PubMed ID: 8949993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]